{
    "nctId": "NCT02019524",
    "briefTitle": "Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients",
    "officialTitle": "Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 39,
    "primaryOutcomeMeasure": "Primary vaccination strategy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients must have breast or ovarian cancer\n2. Patients must have completed primary breast or ovarian cancer therapy (i.e., surgery, chemotherapy, immunotherapy and/or radiation therapy as appropriate per standard of care for patient's specific cancer)\n3. Patients must be without evidence of residual disease as assessed by their treatment team\n4. Patients must be either post-menopausal or surgically post-menopausal\n5. Patients must be HLA-A2 positive\n6. Patients must have a good performance status (ECOG\\<2)\n\nExclusion Criteria:\n\n1. HLA-A2 negative patients\n2. Currently receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate\n3. In poor health (Karnofsky \\<60%, ECOG \\>2)\n4. Total bilirubin \\>1.5, creatinine \\>2, hemoglobin \\<10, platelets \\<50,000, WBC \\<2,000\n5. Active pulmonary disease requiring medication to include multiple inhalers\n6. Of child-bearing age with intact reproductive organs\n7. Involved in other experimental protocols (except with permission of the other study PI)\n8. History of autoimmune disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}